乳腺癌内分泌治疗新药fulvestrant临床研究进展  

Research progress of fulvestrant:A novel drug used in breast cancer endocrine therapy

作　　者：王佳玉[1] 徐兵河[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《癌症进展》2005年第4期342-344,共3页Oncology Progress

摘　　要：Fulvestrant是一种新型雌激素受体(ER)阻滞剂,其降低乳腺癌细胞中ER水平的作用明显优于三苯氧胺(TAM)。初步研究表明,在晚期乳腺癌治疗中,fulvestrant与现有的内分泌治疗药物间无交叉耐药,其疗效略优于TAM,至少与阿那曲唑等效且副作用较小,具有较广泛的应用前景。Fulvestrant is a novel oestrogen receptor(ER)antagonist that has higher efficacy than TAM in downregulating ER.Recent studies suggest that fulvestrant has no cross-resistance with TAM or anromatase inhibitors(Ais).In the treatment of postmenopausal women with advanced breast cancer, fulvestrant has higher effect than TAM and as same as Ais, with good tolerability.So fulvestrant has extensive prospect in breast cancer endocrine therapy.

关 键 词：乳腺癌 内分泌治疗 FULVESTRANT 

分 类 号：R73[医药卫生—肿瘤]